For metastatic and recurrent HNSCC, the Food and Drug Administration has approved immune checkpoint inhibitor (ICI) therapy, including pembrolizumab and nivolumab, which target the programmed cell death protein 1 (PD1) receptor [2, 9, 10]. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.